BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 2015;12:197-212. [PMID: 25421275 DOI: 10.1038/nrclinonc.2014.202] [Cited by in Crossref: 126] [Cited by in F6Publishing: 98] [Article Influence: 15.8] [Reference Citation Analysis]
Number Citing Articles
1 Hong S, Park J, Kwon O, Kim K, Bae G, Cha H. Induction of integrin β3 by sustained ERK activity promotes the invasiveness of TGFβ-induced mesenchymal tumor cells. Cancer Letters 2016;376:339-46. [DOI: 10.1016/j.canlet.2016.04.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
2 Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. Clin Cancer Res. 2017;23:4919-4928. [PMID: 28446508 DOI: 10.1158/1078-0432.ccr-16-2656] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 7.6] [Reference Citation Analysis]
3 Brewer KD, DeBay DR, Dude I, Davis C, Lake K, Parsons C, Rajagopalan R, Weir G, Stanford MM, Mansour M, Bowen CV. Using lymph node swelling as a potential biomarker for successful vaccination. Oncotarget 2016;7:35655-69. [PMID: 27232944 DOI: 10.18632/oncotarget.9580] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
4 Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599-616. [PMID: 30061739 DOI: 10.1038/s41571-018-0073-4] [Cited by in Crossref: 482] [Cited by in F6Publishing: 494] [Article Influence: 160.7] [Reference Citation Analysis]
5 Rejeeth C, Pang X, Zhang R, Xu W, Sun X, Liu B, Lou J, Wan J, Gu H, Yan W, Qian K. Extraction, detection, and profiling of serum biomarkers using designed Fe3O4@SiO2@HA core–shell particles. Nano Res 2018;11:68-79. [DOI: 10.1007/s12274-017-1591-6] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
6 Liu J, Westin SN. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. Gynecol Oncol 2016;141:65-71. [PMID: 27016231 DOI: 10.1016/j.ygyno.2016.01.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Froehlich BC, Popp R, Sobsey CA, Ibrahim S, LeBlanc A, Mohammed Y, Buchanan M, Aguilar-Mahecha A, Pötz O, Chen MX, Spatz A, Basik M, Batist G, Zahedi RP, Borchers CH. A multiplexed, automated immuno-matrix assisted laser desorption/ionization mass spectrometry assay for simultaneous and precise quantitation of PTEN and p110α in cell lines and tumor tissues. Analyst 2021;146:6566-75. [PMID: 34585690 DOI: 10.1039/d1an00165e] [Reference Citation Analysis]
8 Leite KRM, Barrios CH, Buzaid AC, Gagliato D, Gobbi H, Soares F. Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil. Surg Exp Pathol 2021;4. [DOI: 10.1186/s42047-021-00092-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mazzara S, Rossi RL, Grifantini R, Donizetti S, Abrignani S, Bombaci M. CombiROC: an interactive web tool for selecting accurate marker combinations of omics data. Sci Rep 2017;7:45477. [PMID: 28358118 DOI: 10.1038/srep45477] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
10 Loughrey MB, Bankhead P, Coleman HG, Hagan RS, Craig S, McCorry AMB, Gray RT, McQuaid S, Dunne PD, Hamilton PW, James JA, Salto-Tellez M. Validation of the systematic scoring of immunohistochemically stained tumour tissue microarrays using QuPath digital image analysis. Histopathology 2018;73:327-38. [PMID: 29575153 DOI: 10.1111/his.13516] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
11 Sharafeldin M, Bishop GW, Bhakta S, El-Sawy A, Suib SL, Rusling JF. Fe3O4 nanoparticles on graphene oxide sheets for isolation and ultrasensitive amperometric detection of cancer biomarker proteins. Biosens Bioelectron 2017;91:359-66. [PMID: 28056439 DOI: 10.1016/j.bios.2016.12.052] [Cited by in Crossref: 81] [Cited by in F6Publishing: 61] [Article Influence: 13.5] [Reference Citation Analysis]
12 Premaratne G, Farias S, Krishnan S. Pyrenyl carbon nanostructures for ultrasensitive measurements of formaldehyde in urine. Anal Chim Acta 2017;970:23-9. [PMID: 28433055 DOI: 10.1016/j.aca.2017.03.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
13 Popp R, Li H, Leblanc A, Mohammed Y, Aguilar-mahecha A, Chambers AG, Lan C, Poetz O, Basik M, Batist G, Borchers CH. Immuno-Matrix-Assisted Laser Desorption/Ionization Assays for Quantifying AKT1 and AKT2 in Breast and Colorectal Cancer Cell Lines and Tumors. Anal Chem 2017;89:10592-600. [DOI: 10.1021/acs.analchem.7b02934] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
14 Raymond VM, Gray SW, Roychowdhury S, Joffe S, Chinnaiyan AM, Parsons DW, Plon SE; Clinical Sequencing Exploratory Research Consortium Tumor Working Group. Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories. J Natl Cancer Inst 2016;108:djv351. [PMID: 26590952 DOI: 10.1093/jnci/djv351] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
15 Rastmanesh A, Tavakkoli Yaraki M, Wu J, Wang Z, Ghoderao P, Gao Y, Tan YN. Bioinspired micro/nanomotors towards a self-propelled noninvasive diagnosis and treatment of cancer. Mol Syst Des Eng 2021;6:566-93. [DOI: 10.1039/d1me00065a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
16 Polanski R, Vincent J, Polanska UM, Petreus T, Tang EK. Caspase-8 activation by TRAIL monotherapy predicts responses to IAPi and TRAIL combination treatment in breast cancer cell lines. Cell Death Dis 2015;6:e1893. [PMID: 26426685 DOI: 10.1038/cddis.2015.234] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
17 Kamel HFM, Al-Amodi HSAB. Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. Genomics Proteomics Bioinformatics 2017;15:220-35. [PMID: 28813639 DOI: 10.1016/j.gpb.2016.11.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 8.6] [Reference Citation Analysis]
18 Masuda H, Qi Y, Liu S, Hayashi N, Kogawa T, Hortobagyi GN, Tripathy D, Ueno NT. Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. Oncotarget 2017;8:70481-95. [PMID: 29050296 DOI: 10.18632/oncotarget.19719] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
19 Kashyap A, Fomitcheva Khartchenko A, Pati P, Gabrani M, Schraml P, Kaigala GV. Quantitative microimmunohistochemistry for the grading of immunostains on tumour tissues. Nat Biomed Eng 2019;3:478-90. [DOI: 10.1038/s41551-019-0386-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
20 Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, McDonagh CF. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B. PLoS Comput Biol 2016;12:e1004827. [PMID: 27035903 DOI: 10.1371/journal.pcbi.1004827] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
21 Kim H, Lim J, Choi J, Lee H, Son HY, Kim J, Park G, Chun H, Song D, Huh Y, Haam S. Anchored protease-activatable polymersomes for molecular diagnostics of metastatic cancer cells. J Mater Chem B 2017;5:9571-8. [DOI: 10.1039/c7tb01675a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Seymour L, Le Teuff G, Brambilla E, Shepherd FA, Soria J, Kratzke R, Graziano S, Douillard J, Rosell R, Reiman A, Lacas B, Lueza B, Aviel-ronen S, Mcleer A, Le Chevalier T, Pirker R, Filipits M, Dunant A, Pignon J, Tsao M. LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non–small-cell Lung Cancer. Clinical Lung Cancer 2019;20:66-73.e6. [DOI: 10.1016/j.cllc.2018.10.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
23 Tran WT, Lu FI, Salgado R. Tumor infiltrating lymphocytes: current pathways to a standard biomarker in breast cancer. Expert Rev Anticancer Ther 2021;:1-3. [PMID: 34236013 DOI: 10.1080/14737140.2021.1953987] [Reference Citation Analysis]
24 Huang W, Chang CL, Brault ND, Gur O, Wang Z, Jalal SI, Low PS, Ratliff TL, Pili R, Savran CA. Separation and dual detection of prostate cancer cells and protein biomarkers using a microchip device. Lab Chip 2017;17:415-28. [PMID: 28054089 DOI: 10.1039/c6lc01279e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
25 Lodde V, Murgia G, Simula ER, Steri M, Floris M, Idda ML. Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases. Biomolecules 2020;10:E1044. [PMID: 32674342 DOI: 10.3390/biom10071044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
26 Fleisher B, Clarke C, Ait-Oudhia S. Current advances in biomarkers for targeted therapy in triple-negative breast cancer. Breast Cancer (Dove Med Press) 2016;8:183-97. [PMID: 27785100 DOI: 10.2147/BCTT.S114659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
27 Carvalho S, Reis CA, Pinho SS. Cadherins Glycans in Cancer: Sweet Players in a Bitter Process. Trends Cancer 2016;2:519-31. [PMID: 28741480 DOI: 10.1016/j.trecan.2016.08.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
28 Popp R, Li H, Borchers CH. Immuno-MALDI (iMALDI) mass spectrometry for the analysis of proteins in signaling pathways. Expert Review of Proteomics 2018;15:701-8. [DOI: 10.1080/14789450.2018.1516147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
29 Boellner S, Becker KF. Reverse Phase Protein Arrays-Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use. Microarrays (Basel) 2015;4:98-114. [PMID: 27600215 DOI: 10.3390/microarrays4020098] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
30 Rathi V, Wright G, Constantin D, Chang S, Pham H, Jones K, Palios A, Mclachlan SA, Conron M, McKelvie P, Williams R. Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens. Pathology 2017;49:75-82. [PMID: 27913044 DOI: 10.1016/j.pathol.2016.08.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
31 Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018;31:24-38. [PMID: 29148538 DOI: 10.1038/modpathol.2017.104] [Cited by in Crossref: 165] [Cited by in F6Publishing: 140] [Article Influence: 33.0] [Reference Citation Analysis]
32 Ruiz-godoy L, Enríquez-cárcamo V, Suárez-roa L, Lopez-castro ML, Santamaría A, Orozco-morales M, Colín-gonzález AL. Identification of specific pre-analytical quality control markers in plasma and serum samples. Anal Methods 2019;11:2259-71. [DOI: 10.1039/c9ay00131j] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
33 Tang Y, Zou B, Wang R, Luo N, Qi X, Zhou G, Song Q. Multiplex-invasive reaction-assisted qPCR for quantitatively detecting the abundance of EGFR exon 19 deletions in cfDNA. Anal Methods 2020;12:3344-50. [PMID: 32930221 DOI: 10.1039/d0ay00897d] [Reference Citation Analysis]
34 Vivek R, Rejeeth C, Thangam R. Targeted Nanotherapeutics Based on Cancer Biomarkers. Multifunctional Systems for Combined Delivery, Biosensing and Diagnostics. Elsevier; 2017. pp. 229-44. [DOI: 10.1016/b978-0-323-52725-5.00012-5] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
35 Mordente A, Meucci E, Martorana GE, Silvestrini A. Cancer Biomarkers Discovery and Validation: State of the Art, Problems and Future Perspectives. In: Scatena R, editor. Advances in Cancer Biomarkers. Dordrecht: Springer Netherlands; 2015. pp. 9-26. [DOI: 10.1007/978-94-017-7215-0_2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
36 Harton MD, Koh WS, Bunker AD, Singh A, Batchelor E. p53 pulse modulation differentially regulates target gene promoters to regulate cell fate decisions. Mol Syst Biol 2019;15:e8685. [PMID: 31556489 DOI: 10.15252/msb.20188685] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
37 Kel AE. Search for Master Regulators in Walking Cancer Pathways. Methods Mol Biol 2017;1613:161-91. [PMID: 28849562 DOI: 10.1007/978-1-4939-7027-8_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
38 Satoh M, Takano S, Sogawa K, Noda K, Yoshitomi H, Ishibashi M, Mogushi K, Takizawa H, Otsuka M, Shimizu H, Miyazaki M, Nomura F. Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer. Cancer Sci. 2017;108:795-803. [PMID: 28161904 DOI: 10.1111/cas.13181] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
39 Wang C, Ding S, Wang S, Shi Z, Pandey NK, Chudal L, Wang L, Zhang Z, Wen Y, Yao H, Lin L, Chen W, Xiong L. Endogenous tumor microenvironment-responsive multifunctional nanoplatforms for precision cancer theranostics. Coordination Chemistry Reviews 2021;426:213529. [DOI: 10.1016/j.ccr.2020.213529] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
40 Carper MB, Claudio PP. Clinical potential of gene mutations in lung cancer. Clin Transl Med 2015;4:33. [PMID: 26603430 DOI: 10.1186/s40169-015-0074-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
41 Siderowf A, Aarsland D, Mollenhauer B, Goldman JG, Ravina B. Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials: Biomarkers of Cognitive Impairment. Mov Disord 2018;33:528-36. [DOI: 10.1002/mds.27355] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
42 Anwar SL, Lehmann U. MicroRNAs: Emerging Novel Clinical Biomarkers for Hepatocellular Carcinomas. J Clin Med. 2015;4:1631-1650. [PMID: 26295264 DOI: 10.3390/jcm4081631] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
43 Fokas E, Rödel C. Targeted agents in GI radiotherapy: Clinical efficacy and side effects. Best Pract Res Clin Gastroenterol 2016;30:537-49. [PMID: 27644903 DOI: 10.1016/j.bpg.2016.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
44 Hinneburg H, Korać P, Schirmeister F, Gasparov S, Seeberger PH, Zoldoš V, Kolarich D. Unlocking Cancer Glycomes from Histopathological Formalin-fixed and Paraffin-embedded (FFPE) Tissue Microdissections. Mol Cell Proteomics 2017;16:524-36. [PMID: 28122943 DOI: 10.1074/mcp.M116.062414] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
45 Widodo SS, Hutchinson RA, Fang Y, Mangiola S, Neeson PJ, Darcy PK, Barrow AD, Hovens CM, Dinevska M, Stylli SS, Mantamadiotis T. Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. Cancer Immunol Immunother 2021;70:1811-20. [PMID: 33389014 DOI: 10.1007/s00262-020-02801-7] [Reference Citation Analysis]
46 Riazifar M, Pone EJ, Lötvall J, Zhao W. Stem Cell Extracellular Vesicles: Extended Messages of Regeneration. Annu Rev Pharmacol Toxicol 2017;57:125-54. [PMID: 27814025 DOI: 10.1146/annurev-pharmtox-061616-030146] [Cited by in Crossref: 133] [Cited by in F6Publishing: 129] [Article Influence: 22.2] [Reference Citation Analysis]
47 Liu C, Rohart F, Simpson PT, Khanna KK, Ragan MA, Lê Cao KA. Integrating Multi-omics Data to Dissect Mechanisms of DNA repair Dysregulation in Breast Cancer. Sci Rep 2016;6:34000. [PMID: 27666291 DOI: 10.1038/srep34000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
48 Aberuyi N, Rahgozar S, Ghodousi ES, Ghaedi K. Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia. Front Oncol 2019;9:1496. [PMID: 32010613 DOI: 10.3389/fonc.2019.01496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Chałupniak A, Morales-narváez E, Merkoçi A. Micro and nanomotors in diagnostics. Advanced Drug Delivery Reviews 2015;95:104-16. [DOI: 10.1016/j.addr.2015.09.004] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 13.3] [Reference Citation Analysis]
50 Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Dürig J, Ringshausen I, Zapatka M, Huber W, Zenz T. Drug-perturbation-based stratification of blood cancer. J Clin Invest 2018;128:427-45. [PMID: 29227286 DOI: 10.1172/JCI93801] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 12.4] [Reference Citation Analysis]
51 Everett BM, Ridker PM. Biomarkers for Cardiovascular Screening: Progress or Passé? Clinical Chemistry 2017;63:248-51. [DOI: 10.1373/clinchem.2016.254854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
52 Fledrich R, Mannil M, Leha A, Ehbrecht C, Solari A, Pelayo-Negro AL, Berciano J, Schlotter-Weigel B, Schnizer TJ, Prukop T, Garcia-Angarita N, Czesnik D, Haberlová J, Mazanec R, Paulus W, Beissbarth T, Walter MC, Triaal C, Hogrel JY, Dubourg O, Schenone A, Baets J, De Jonghe P, Shy ME, Horvath R, Pareyson D, Seeman P, Young P, Sereda MW. Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. J Neurol Neurosurg Psychiatry 2017;88:941-52. [PMID: 28860329 DOI: 10.1136/jnnp-2017-315721] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
53 Zeron-medina J, Ochoa de Olza M, Braña I, Rodon J. The Personalization of Therapy: Molecular Profiling Technologies and Their Application. Seminars in Oncology 2015;42:775-87. [DOI: 10.1053/j.seminoncol.2015.09.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
54 Olaussen KA, Postel-Vinay S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Ann Oncol 2016;27:2004-16. [PMID: 27502726 DOI: 10.1093/annonc/mdw321] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 10.0] [Reference Citation Analysis]
55 Bombaci M, Rossi RL. Computation and Selection of Optimal Biomarker Combinations by Integrative ROC Analysis Using CombiROC. Methods Mol Biol 2019;1959:247-59. [PMID: 30852827 DOI: 10.1007/978-1-4939-9164-8_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Rodrigues-Ferreira S, Nehlig A, Moindjie H, Monchecourt C, Seiler C, Marangoni E, Chateau-Joubert S, Dujaric ME, Servant N, Asselain B, de Cremoux P, Lacroix-Triki M, Arnedos M, Pierga JY, André F, Nahmias C. Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy. Proc Natl Acad Sci U S A 2019;116:23691-7. [PMID: 31685623 DOI: 10.1073/pnas.1910824116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
57 Szturz P, Budíková M, Vermorken JB, Horová I, Gál B, Raymond E, de Gramont A, Faivre S. Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data. Oral Oncol 2017;74:68-76. [PMID: 29103754 DOI: 10.1016/j.oraloncology.2017.09.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
58 Lucas JL, Tacheny EA, Ferris A, Galusha M, Srivastava AK, Ganguly A, Williams PM, Sachs MC, Thurin M, Tricoli JV, Ricker W, Gildersleeve JC. Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy. PLoS One 2017;12:e0182739. [PMID: 28771597 DOI: 10.1371/journal.pone.0182739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
59 Burris HA, Saltz LB, Yu PP. Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment. Am Soc Clin Oncol Educ Book 2018;38:139-46. [PMID: 30231307 DOI: 10.1200/EDBK_200825] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
60 Sun L, Lin Y, Wang G, Zhang L, Hu L, Lu Z. Correlation of zinc finger protein 2, a prognostic biomarker, with immune infiltrates in liver cancer. Biosci Rep 2021;41:BSR20203115. [PMID: 33439969 DOI: 10.1042/BSR20203115] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Sinn HP, Schneeweiss A, Keller M, Schlombs K, Laible M, Seitz J, Lakis S, Veltrup E, Altevogt P, Eidt S, Wirtz RM, Marmé F. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer 2017;17:124. [PMID: 28193205 DOI: 10.1186/s12885-017-3111-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 7.4] [Reference Citation Analysis]
62 Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, Mccabe C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N, Mckane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D. Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT. Programme Grants Appl Res 2018;6:1-528. [DOI: 10.3310/pgfar06030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
63 Byrne JA, Grima N, Capes-Davis A, Labbé C. The Possibility of Systematic Research Fraud Targeting Under-Studied Human Genes: Causes, Consequences, and Potential Solutions. Biomark Insights 2019;14:1177271919829162. [PMID: 30783377 DOI: 10.1177/1177271919829162] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
64 Guedes LB, Morais CL, Almutairi F, Haffner MC, Zheng Q, Isaacs JT, Antonarakis ES, Lu C, Tsai H, Luo J, De Marzo AM, Lotan TL. Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clin Cancer Res 2016;22:4651-63. [PMID: 27166397 DOI: 10.1158/1078-0432.CCR-16-0205] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
65 Greytak SR, Engel KB, Zmuda E, Casas-Silva E, Guan P, Hoadley KA, Mungall AJ, Wheeler DA, Doddapaneni HV, Moore HM. National Cancer Institute Biospecimen Evidence-Based Practices: Harmonizing Procedures for Nucleic Acid Extraction from Formalin-Fixed, Paraffin-Embedded Tissue. Biopreserv Biobank 2018;16:247-50. [PMID: 29920119 DOI: 10.1089/bio.2018.0046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
66 Flippot R, Massard C, Auclin E, Azria D, Bourien H, Rochigneux P, Schernberg A, Verlingue L, Zafrani L, Vignot S. Quelle vision des biomarqueurs en 2017 ? Promesses et défis de la médecine personnalisée en oncologie. Bulletin du Cancer 2017;104:735-43. [DOI: 10.1016/j.bulcan.2017.07.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
67 Lara Gongora AB, Carvalho Oliveira LJ, Jardim DL. Impact of the biomarker enrichment strategy in drug development. Expert Review of Molecular Diagnostics 2020;20:611-8. [DOI: 10.1080/14737159.2020.1711734] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, Lyng H. Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity. EBioMedicine 2020;57:102841. [PMID: 32580139 DOI: 10.1016/j.ebiom.2020.102841] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
69 Rukhlenko OS, Khorsand F, Krstic A, Rozanc J, Alexopoulos LG, Rauch N, Erickson KE, Hlavacek WS, Posner RG, Gómez-Coca S, Rosta E, Fitzgibbon C, Matallanas D, Rauch J, Kolch W, Kholodenko BN. Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. Cell Syst 2018;7:161-179.e14. [PMID: 30007540 DOI: 10.1016/j.cels.2018.06.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
70 Naulaerts S, Dang CC, Ballester PJ. Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours. Oncotarget 2017;8:97025-40. [PMID: 29228590 DOI: 10.18632/oncotarget.20923] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
71 Dang CC, Peón A, Ballester PJ. Unearthing new genomic markers of drug response by improved measurement of discriminative power. BMC Med Genomics 2018;11:10. [PMID: 29409485 DOI: 10.1186/s12920-018-0336-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
72 Tan TZ, Yang H, Ye J, Low J, Choolani M, Tan DS, Thiery JP, Huang RY. CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. Oncotarget 2015;6:43843-52. [PMID: 26549805 DOI: 10.18632/oncotarget.5983] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
73 Hierro C, Azaro A, Argilés G, Elez E, Gómez P, Carles J, Rodon J. Unveiling changes in the landscape of patient populations in cancer early drug development. Oncotarget 2017;8:14158-72. [PMID: 27835915 DOI: 10.18632/oncotarget.13258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
74 Adamczyk LA, Williams H, Frankow A, Ellis HP, Haynes HR, Perks C, Holly JM, Kurian KM. Current Understanding of Circulating Tumor Cells - Potential Value in Malignancies of the Central Nervous System. Front Neurol 2015;6:174. [PMID: 26322014 DOI: 10.3389/fneur.2015.00174] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
75 Barsanti-Innes B, Hey SP, Kimmelman J. The Challenges of Validating in Precision Medicine: The Case of Excision Repair Cross-Complement Group 1 Diagnostic Testing. Oncologist 2017;22:89-96. [PMID: 28126916 DOI: 10.1634/theoncologist.2016-0188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Kim HN, Habbit NL, Su C, Choi N, Ahn EH, Lipke EA, Kim D. Microphysiological Systems as Enabling Tools for Modeling Complexity in the Tumor Microenvironment and Accelerating Cancer Drug Development. Adv Funct Mater 2019;29:1807553. [DOI: 10.1002/adfm.201807553] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
77 Aleskandarany MA, Vandenberghe ME, Marchiò C, Ellis IO, Sapino A, Rakha EA. Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. Pathobiology 2018;85:23-34. [DOI: 10.1159/000477851] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
78 Lommen K, Odeh S, Theije CC, Smits KM. Biobanking in Molecular Biomarker Research for the Early Detection of Cancer. Cancers (Basel) 2020;12:E776. [PMID: 32218259 DOI: 10.3390/cancers12040776] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
79 Nguyen L, Dang CC, Ballester PJ. Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data. F1000Res 2016;5:ISCB Comm J-2927. [PMID: 28299173 DOI: 10.12688/f1000research.10529.2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
80 Patel SB, Gill D, Garrido-Laguna I. Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Onco Targets Ther 2016;9:75-86. [PMID: 26770060 DOI: 10.2147/OTT.S68558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
81 Lih C, Takebe N. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience. Current Problems in Cancer 2017;41:201-11. [DOI: 10.1016/j.currproblcancer.2017.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
82 Jardim DL, Groves ES, Breitfeld PP, Kurzrock R. Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. Cancer Treat Rev 2017;52:12-21. [PMID: 27883925 DOI: 10.1016/j.ctrv.2016.10.009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
83 Engebraaten O, Yau C, Berg K, Borgen E, Garred Ø, Berstad MEB, Fremstedal ASV, DeMichele A, Veer LV', Esserman L, Weyergang A. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. Nat Commun 2021;12:6427. [PMID: 34741021 DOI: 10.1038/s41467-021-26018-z] [Reference Citation Analysis]
84 Taylor MA. Circulating MicroRNAs as Biomarkers and Mediators of Cell-Cell Communication in Cancer. Biomedicines 2015;3:270-81. [PMID: 28536412 DOI: 10.3390/biomedicines3040270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
85 Ambekar RS, Kandasubramanian B. A polydopamine-based platform for anti-cancer drug delivery. Biomater Sci 2019;7:1776-93. [PMID: 30838354 DOI: 10.1039/c8bm01642a] [Cited by in Crossref: 49] [Cited by in F6Publishing: 6] [Article Influence: 16.3] [Reference Citation Analysis]
86 Wagle MC, Kirouac D, Klijn C, Liu B, Mahajan S, Junttila M, Moffat J, Merchant M, Huw L, Wongchenko M, Okrah K, Srinivasan S, Mounir Z, Sumiyoshi T, Haverty PM, Yauch RL, Yan Y, Kabbarah O, Hampton G, Amler L, Ramanujan S, Lackner MR, Huang SA. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis Oncol 2018;2:7. [PMID: 29872725 DOI: 10.1038/s41698-018-0051-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
87 Hey SP, Kesselheim AS. BIOMEDICAL RESEARCH. Countering imprecision in precision medicine. Science 2016;353:448-9. [PMID: 27471295 DOI: 10.1126/science.aaf5101] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
88 Jardim DL, Schwaederle M, Hong DS, Kurzrock R. An appraisal of drug development timelines in the Era of precision oncology. Oncotarget 2016;7:53037-46. [PMID: 27419632 DOI: 10.18632/oncotarget.10588] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
89 Papadakis ES, Reeves T, Robson NH, Maishman T, Packham G, Cutress RI. BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses. Br J Cancer 2017;116:1585-94. [PMID: 28510570 DOI: 10.1038/bjc.2017.130] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
90 Hoffman MA, Fang B, Haura EB, Rix U, Koomen JM. Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 2018;17:63-75. [PMID: 29164889 DOI: 10.1021/acs.jproteome.7b00329] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
91 Eduati F, Doldàn-Martelli V, Klinger B, Cokelaer T, Sieber A, Kogera F, Dorel M, Garnett MJ, Blüthgen N, Saez-Rodriguez J. Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models. Cancer Res 2017;77:3364-75. [PMID: 28381545 DOI: 10.1158/0008-5472.CAN-17-0078] [Cited by in Crossref: 67] [Cited by in F6Publishing: 33] [Article Influence: 13.4] [Reference Citation Analysis]
92 Chen SL, Lu SX, Liu LL, Wang CH, Yang X, Zhang ZY, Zhang HZ, Yun JP. eEF1A1 Overexpression Enhances Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma. Transl Oncol 2018;11:125-31. [PMID: 29248802 DOI: 10.1016/j.tranon.2017.11.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
93 Bouattour M, Soubrane O, de Gramont A, Faivre S. Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM. Trials 2016;17:563. [PMID: 27887632 DOI: 10.1186/s13063-016-1675-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
94 Nguyen L, Dang CC, Ballester PJ. Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data. F1000Res 2016;5:ISCB Comm J-2927. [PMID: 28299173 DOI: 10.12688/f1000research.10529.2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
95 Jones AL, Dhanapala L, Baldo TA, Sharafeldin M, Krause CE, Shen M, Moghaddam S, Faria RC, Dey DK, Watson RW, Andrawis R, Lee NH, Rusling JF. Prostate Cancer Diagnosis in the Clinic Using an 8-Protein Biomarker Panel. Anal Chem 2021;93:1059-67. [PMID: 33289381 DOI: 10.1021/acs.analchem.0c04034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
96 Bayar MA, Antoun S, Lanoy E. Statistical approaches for evaluating body composition markers in clinical cancer research. Expert Rev Anticancer Ther 2017;17:311-8. [PMID: 28277100 DOI: 10.1080/14737140.2017.1298446] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
97 Sin DD, Hollander Z, DeMarco ML, McManus BM, Ng RT. Biomarker Development for Chronic Obstructive Pulmonary Disease. From Discovery to Clinical Implementation. Am J Respir Crit Care Med 2015;192:1162-70. [PMID: 26176936 DOI: 10.1164/rccm.201505-0871PP] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
98 Strandberg K, Ayoglu B, Roos A, Reza M, Niks E, Signorelli M, Fasterius E, Pontén F, Lochmüller H, Domingos J, Ala P, Muntoni F, Aartsma-Rus A, Spitali P, Nilsson P, Szigyarto CA. Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy. J Neuromuscul Dis 2020;7:231-46. [PMID: 32390640 DOI: 10.3233/JND-190454] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
99 Froehlich BC, Popp R, Sobsey CA, Ibrahim S, LeBlanc AM, Mohammed Y, Aguilar-Mahecha A, Poetz O, Chen MX, Spatz A, Basik M, Batist G, Zahedi RP, Borchers CH. Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer Cells. Proteomics Clin Appl 2020;14:e2000034. [PMID: 32643306 DOI: 10.1002/prca.202000034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
100 Watson MM, Søreide K. The prognostic yield of biomarkers harvested in chemotherapy-naive stage II colon cancer: can we separate the wheat from the chaff? Mol Med 2016;22:271-3. [PMID: 27262159 DOI: 10.2119/molmed.2016.00098] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
101 Rodrigues D, Monteiro M, Jerónimo C, Henrique R, Belo L, Bastos ML, Guedes de Pinho P, Carvalho M. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems. Transl Res 2017;180:1-11. [PMID: 27546593 DOI: 10.1016/j.trsl.2016.07.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
102 Giudici F, Petracci E, Nanni O, Bottin C, Pinamonti M, Zanconati F, Scaggiante B. Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis. PLoS One 2019;14:e0218030. [PMID: 31220107 DOI: 10.1371/journal.pone.0218030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]